-
The era of strong medical equipment supervision has come, and medical equipment personnel will face the normalization of unannounced inspections
Time of Update: 2021-09-30
The notice pointed out that for the 45 general defects found in the inspection, the Sichuan Provincial Drug Administration has ordered relevant companies to rectify within a time limit, and required companies to implement the main responsibility for quality and safety, analyze and find reasons, evaluate safety risks, and for those that may cause safety hazards, Recall related products in accordance with the "Medical Device Recall Management Measures" .
-
Experts remind: Periodontitis is the primary factor leading to tooth loss
Time of Update: 2021-09-30
Liu Yuzhi said that special attention should be paid to several stages in the prevention, treatment, and control of periodontal disease .
Liu Yuzhi said that special attention should be paid to several stages in the prevention, treatment, and control of periodontal disease .
-
Cinda Biotech announced that the National Medical Products Administration has accepted the application for new indications for the treatment of first-line esophageal squamous cell carcinoma patients with daboshu (sintilimab injection) combined with chemotherapy
Time of Update: 2021-09-30
San Francisco, USA and Suzhou, China September 23, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales f
-
Zheng Xiangling, Chairman of Beijing Tide Pharmaceuticals, was elected as a member of the Hong Kong Special Administrative Region Election Committee
Time of Update: 2021-09-30
On September 19, the 2021 election of the Hong Kong Special Administrative Region Election Committee was successfully concluded.
Zheng Xiangling, executive director of the China Overseas Friendship Association and chairman of the Hong Kong Provincial Committee of the CPPCC Committee, said that the election of the Election Committee was carried out smoothly and orderly.
-
The pharmaceutical track continues to develop well, and many sub-sectors are highly favored by investors
Time of Update: 2021-09-30
After quitting Hengrui Pharmaceutical’s top ten shareholders in 2017, Hillhouse re-purchased more than 40 million shares of Hengrui Pharmaceuticals in the second quarter of this year, becoming one of its largest shareholders, holding a market value of approximately 2.
-
MS oral new medicine!
Time of Update: 2021-09-30
The results of the primary endpoint showed that compared with Tecfidera, patients treated with Vumerity had a 46% reduction in the number of days with self-reported IGISIS intensity scores ≥2 (adjusted odds ratio [95%CI]: 0.
-
Luye Pharma's Alzheimer's innovative drug Liss' Mingdo Day transdermal patch is approved for marketing in the UK
Time of Update: 2021-09-30
Guildford, United Kingdom, September 23, 2021/PRNewswire/ - Luye Pharmaceutical Group announced that its self-developed innovative preparation, Liss’ Mindo Day Transdermal Patch, has been approved by the British Drug and Health Products Regulatory Agency ( Medicines and Healthcare products Regulatory Agency) for the treatment of mild and moderate dementia related to Alzheimer’s disease .
-
Zhejiang Pharmaceutical Levofloxacin Sodium Chloride Injection Obtained Drug Registration Certificate
Time of Update: 2021-09-30
On September 22, Zhejiang Medicine issued an announcement stating that the company had recently received the "Drug Registration Certificate" for levofloxacin sodium chloride injection 150ml: 0.
-
Antu Biocarbohydrate Antigen CA15-3 Calibrator Obtained Medical Device Registration Certificate
Time of Update: 2021-09-30
On September 22, Antu Biological issued an announcement stating that the company had recently received the "Medical Device Registration Certificate" for the carbohydrate antigen CA15-3 calibrator issued by the Henan Provincial Drug Administration for use in the company's fully automated chemiluminescence detection.
-
Ascent Pharmaceuticals MDM2-p53 inhibitor APG-115 obtained Fast Track qualification from the US FDA for the treatment of relapsed/refractory unresectable/metastatic melanoma
Time of Update: 2021-09-30
HK) announced today that the company’s original innovative drug MDM2-p53 inhibitor alrizomadlin (APG-115) has been granted Fast Track Qualification (FTD) by the US Food and Drug Administration (FDA) for use in tumor immunity Patients with relapsed/refractory unresectable/metastatic melanoma after treatment .
-
Bribery, collection and cut-off of Yichang people’s welfare, and Baiao Pharmaceutical’s “blacklist” of dishonesty face heavy penalties
Time of Update: 2021-09-30
According to the announcement, two pharmaceutical companies, Yichang Renfu Pharmaceutical and Beijing Baiao Pharmaceutical, were rated as "serious" in Henan Province's medical prices and credit untrustworthiness due to commercial bribery and centralized procurement .
-
Within a week, many pharmaceutical companies such as Jianfan Biological and Jingxin Pharmaceutical were investigated by institutions
Time of Update: 2021-09-30
A number of pharmaceutical companies have recently disclosed the announcements of obtaining institutional research, including Jianfan Biological, Tonghe Pharmaceutical, Jingxin Pharmaceutical, China Resources Sanjiu, etc.
-
Aerie's new drug for dry eye disease failed in mid-term research, chairman and CEO resigned
Time of Update: 2021-09-30
In the news of the failure to disclose, Anido downplayed its importance, believing that "this is a phase IIb study and there is no need to choose the primary endpoint .
-
With the development of the traditional Chinese medicine industry, pharmaceutical companies urgently need to transform and upgrade
Time of Update: 2021-09-30
According to the "In-depth Research and Investment Prospect Analysis Report of the Traditional Chinese Medicine Industry Market 2021-2025" released by the New Thinking Industry Research Center, the scale of China's traditional Chinese medicine manufacturing market has increased from 64 billion yuan to 73.
-
All localities are accelerating the implementation of the standard of traditional Chinese medicine formula particles!
Time of Update: 2021-09-30
On August 12, the Shandong Provincial Food and Drug Administration issued the "Shandong Province Traditional Chinese Medicine Formula Granule Production Quality Management Guidelines (Trial)", which put forward quality management requirements for the institutions and personnel of the manufacturing enterprises, plants and facilities, and equipment .
-
Chen Yu serves as Vice President of Biological Research and Head of Translational Medicine Research of Yahong New Drug Discovery Department
Time of Update: 2021-09-30
He organized and led a team to commit to the company’s new drug discovery project and translational medicine research in the field of tumor immunotherapy, and promoted multiple projects into clinical and preclinical research.
-
Domestic pharmaceutical companies are vigorously introducing innovative drugs, and hundreds of millions of transactions have become the norm
Time of Update: 2021-09-30
It is understood that since the beginning of this year, domestic pharmaceutical companies have spent huge sums of money to introduce innovative drugs has become the norm in the industry, and transactions with hundreds of millions of dollars are not rare .
-
CSCO2021 Professor Li Jin: New Hope for HER2 Positive Solid Tumors New ADC Drug MRG002 Phase I Study Announced
Time of Update: 2021-09-29
On September 25-29, 2021, the 24th National Conference on Clinical Oncology and the 2021 CSCO Academic Annual Meeting will be held as scheduled to promote the continuous development of China's oncolog
-
As the domestic ADC drug market continues to develop, competition is increasing
Time of Update: 2021-09-29
The announcement showed that SHR-A1904 for injection is an antibody-drug conjugate targeting tumor-specific antigens.
In recent years, with the continuous maturity of ADC drug research and development technology, this market has gradually become hot, and it is attracting more and more companies to enter this field .
-
No entry: Neurology clinic refuses to use Aduhelm, a new drug for Alzheimer's disease
Time of Update: 2021-09-29
According to a note on its website, considering the high price of Aduhelm-the average annual treatment cost per patient is $56,000-and the ambiguous clinical benefits, doctors at the Neurology Center have agreed to refuse to use it until the dispute is clarified.
